Parameter
| Biomarker | FLT3 mutation (ITD/TKD) | Full name | Fms-Like Tyrosine Kinase 3 gene mutation (Internal Tandem Duplication/Tyrosine Kinase Domain) | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, prognosis, therapeutic targets |
| Disease | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Whole blood/bone marrow (gene sequencing, DNA fragment analysis) | ||
| Pathobiological Mechanisms | Type III receptor tyrosine kinase, upon mutation, activates pathways such as STAT5 and RAS/MAPK, driving abnormal proliferation of hematopoietic cells. | ||||
| Clinical Availability Status | Clinically available/under targeted therapy: key prognostic stratification indicators, with targeted drugs already approved. | ||||
| Notes and Dynamics | ITD mutations are associated with poorer prognosis than TKD, and the higher the allele ratio, the worse the prognosis. Inhibitors such as sorafenib and midostaurin require combination with chemotherapy to improve resistance. | ||||